Antitumor Activity of Vinflunine: Effector Pathways and Potential for Synergies

Seminars in Oncology

Volumn 35, Issue SUPPL 3, 2008, Pages

  Braguer, Diane ^a   Barret, Jean Marc ^b   McDaid, Hayley ^c   Kruczynski, Anna ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 3 BLOCKING AGENT; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TRASTUZUMAB; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE; VINFLUNINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CANCER; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SENSITIVITY; DRUG TOLERABILITY; GLIOMA; HUMAN; KIDNEY CANCER; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; MYELOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICROTUBULES; SIGNAL TRANSDUCTION; TUBULIN MODULATORS; VINBLASTINE;

EID: 44449132575     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.01.011     Document Type: Article

References (42)

1. Kruczynski A., Colpaert F., Tarayre J.P., Mouillard P., Fahy J., and Hill B.T. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41 (1998) 437-447
2. Cros S., Wright M., Morimoto M., Lataste H., Couzinier J.P., and Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol 16 Suppl 4 (1989) 15-20
3. Hill B.T., Fiebig H.H., Waud W.R., Poupon M.F., Colpaert F., and Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35 (1999) 512-520
4. Kruczynski A., and Hill B.T. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 40 (2001) 159-173
5. Bonfil R.D., Russo D.M., Binda M.M., Delgado F.M., and Vincenti M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 7 (2002) 159-166
6. Kruczynski A., Barret J.M., Etievant C., Colpaert F., Fahy J., and Hill B.T. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55 (1998) 635-648
7. Okouneva T., Hill B.T., Wilson L., and Jordan M.A. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2 (2003) 427-436
8. Pourroy B., Carre M., Honore S., Bourgarel-Rey V., Kruczynski A., Briand C., et al. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol 66 (2004) 580-591
9. Srivastava R.K., Srivastava A.R., Korsmeyer S.J., Nesterova M., Cho-Chung Y.S., and Longo D.L. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18 (1998) 3509-3517
10. Toh H.C., Sun L., Koh C.H., and Aw S.E. Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine. Leuk Lymphoma 31 (1998) 195-208
11. Wyllie A.H. Apoptosis: an overview. Br Med Bull 53 (1997) 451-465
12. Miller D.K. The role of the Caspase family of cysteine proteases in apoptosis. Semin Immunol 9 (1997) 35-49
13. Esteve M.A., Carré M., and Braguer D. Microtubules in apoptosis induction: Are they necessary?. Curr Cancer Drug Targets 7 (2007) 325-334
14. Wang L.G., Liu X.M., Kreis W., and Budman D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44 (1999) 355-361
15. Stone A.A., and Chambers T.C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 254 (2000) 110-119
16. Kruczynski A., Etievant C., Perrin D., Chansard N., Duflos A., and Hill B.T. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer 86 (2002) 143-150
17. Wang T.H., Wang H.S., Ichijo H., Giannakakou P., Foster J.S., Fojo T., et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 273 (1998) 4928-4936
18. Estève M.A., Carré M., Bourgarel-Rey V., Kruczynski A., Raspaglio G., Ferlini C., et al. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther 5 (2006) 2824-2833
19. Taraboletti G., and Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 1 (2001) 378-384
20. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
21. Pasquier E., Honoré S., and Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand?. Drug Resist Updat 9 (2006) 74-86
22. Vacca A., Iurlaro M., Ribatti D., Minischetti M., Nico B., Ria R., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94 (1999) 4143-4155
23. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2 (1996) 1843-1849
24. Pasquier E., Honore S., Pourroy B., Jordan M.A., Lehmann M., Briand C., et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65 (2005) 2433-2440
25. Pourroy B., Honoré S., Pasquier E., Bourgarel-Rey V., Kruczynski A., Briand C., et al. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 66 (2006) 3256-3263
26. Kruczynski A., Poli M., Dossi R., Chazottes E., Berrichon G., Ricome C., et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 42 (2006) 2821-2832
27. Holwell S.E., Hill B.T., and Bibby M.C. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 84 (2001) 290-295
28. Barret J.M., Etievant C., and Hill B.T. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 45 (2000) 471-476
29. Ramlau R., Souquet P., Sun X., et al. Results of a phase I/II and pharmacokinetic study of vinflunine VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC). [abstract 7110]. J Clin Oncol (Meeting Abstracts) 22 14S (2004) 643s
30. Souquet P, Ramlau R, Sun X, et al. Vinflunine (VFL) and cisplatin (CDDP) combination in first line treatment of advanced non-small-cell lung cancer (NSCLC). Final results of a phase II study. Paper presented at the World Conference on Lung Cancer; July 3, 2005; Barcelona, Spain. Poster 571.
31. Lemarie E., Bennouna J., Grossi F., et al. Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (ptd): preliminary results of the phase I and pharmacokinetic study. [abstract 7266]. J Clin Oncol 23 16S (2005) 686s
32. Tourani J., Pinel M., Planchard D., Aslanis V., Gouva S., and Robinet G. Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): final results. [abstract 7271]. J Clin Oncol 23 16S (2005) 688s
33. Campone M, Fumoleau P, Roche H, Bonneterre J, et al. A dose-finding and pharmacokinetic study of IV vinflunine (VFL) in combination with capecitabine (CAPE) as second line treatment of metastatic breast cancer (MBC). Presented at the San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, TX.
34. Paz K., and Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front Biosci 10 (2005) 1415-1439
35. Reid A., Vidal L., Shaw H., and de B.J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43 (2007) 481-489
36. Peacock N.W., Spigel D.R., Mainwaring P.N., et al. Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer. [abstract 1043]. J Clin Oncol 28 18S (2007) 42s
37. Paridaens R., Wildiers H., et al. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer (2007), American Society of Clinical Oncology, Chicago, IL
38. Catalogue of Somatic Mutations in Cancer. http://www.sanger.ac.uk/perl/genetics/CGP/cosmic (Accessed Dec 19, 2007)
39. Knowles M.A. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 25 (2007) 581-593
40. Simoens C., Vermorken J.B., Korst A.E., et al. Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemother Pharmacol 58 (2006) 210-218
41. Simoens C., Pauwels B., Vermorken J.B., Patyn G.G., Lambreckts H.A., Breillout F., et al. Further mechanistic unraveling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro. Cancer Chemother Pharmacol (2008) In press
42. Venditti J.M. Preclinical drug development: Rationale and methods. Semin Oncol 8 (1981) 349-361